{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:42:20Z","timestamp":1793580140471,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s11920-019-1049-5","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T02:02:47Z","timestamp":1561946567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":261,"title":["Management of Behavioral and Psychological Symptoms of Dementia"],"prefix":"10.1007","volume":"21","author":[{"given":"Laurel J.","family":"Bessey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Art","family":"Walaszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,1]]},"reference":[{"key":"1049_CR1","unstructured":"Prince M, Guerchet M, Prina M. Policy brief for heads of government: the global impact of dementia 2013\u20132050. Alzheimer\u2019s disease international; 2013."},{"issue":"2","key":"1049_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1176\/jnp.12.2.233","volume":"12","author":"DI Kaufer","year":"2000","unstructured":"Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the neuropsychiatric inventory. J Neuropsychiatr Clin Neurosci. 2000;12(2):233\u20139.","journal-title":"J Neuropsychiatr Clin Neurosci"},{"key":"1049_CR3","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jalz.2011.05.2410","volume":"7","author":"CG Lyketsos","year":"2011","unstructured":"Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, et al. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement. 2011;7. United States: Copyright (c) 2011 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved:532\u20139.","journal-title":"Alzheimers Dement"},{"key":"1049_CR4","doi-asserted-by":"publisher","first-page":"h369","DOI":"10.1136\/bmj.h369","volume":"350","author":"HC Kales","year":"2015","unstructured":"Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369.","journal-title":"BMJ."},{"issue":"5","key":"1049_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/gps.490","volume":"17","author":"MS Beeri","year":"2002","unstructured":"Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry. 2002;17(5):403\u20138.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"1049_CR6","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/jgs.12730","volume":"62","author":"HC Kales","year":"2014","unstructured":"Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"1049_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11920-017-0818-2","volume":"19","author":"ST Cheng","year":"2017","unstructured":"Cheng ST. Dementia caregiver burden: a research update and critical analysis. Curr Psychiatry Rep. 2017;19(9):64.","journal-title":"Curr Psychiatry Rep"},{"issue":"12","key":"1049_CR8","doi-asserted-by":"publisher","first-page":"941","DOI":"10.7326\/0003-4819-113-12-941","volume":"113","author":"SK Inouye","year":"1990","unstructured":"Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990;113(12):941\u20138.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1049_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12877-018-0801-8","volume":"18","author":"HC Kales","year":"2018","unstructured":"\u2022 Kales HC, Gitlin LN, Stanislawski B, Myra Kim H, Marx K, Turnwald M, et al. Effect of the WeCareAdvisor on family caregiver outcomes in dementia: a pilot randomized controlled trial. BMC Geriatr. 2018;18(1):113 This pilot RCT examines a web-based toold developed to enable family caregivers to assess, manage, and track BPSD.","journal-title":"BMC Geriatr"},{"key":"1049_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2147\/CIA.S138836","volume":"13","author":"CA Surr","year":"2018","unstructured":"\u2022 Surr CA, Griffiths AW, Kelley R. Implementing dementia care mapping as a practice development tool in dementia care services: a systematic review. Clin Interv Aging. 2018;13:165\u201377 This systematic review discusses dementia care mapping including barriers, and information about implementation.","journal-title":"Clin Interv Aging"},{"key":"1049_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-3-319-16068-9_7","volume-title":"Geriatrics models of care: bringing \u2018best practice\u2019 to an aging","author":"T Howell","year":"2015","unstructured":"Howell T. The Wisconsin Star method: understanding and addressing complexity in geriatrics. In: Malone M, Capezuti E, Palmer R, editors. Geriatrics models of care: bringing \u2018best practice\u2019 to an aging. America: Springer International Publishing; 2015. p. 87\u201394."},{"key":"1049_CR12","unstructured":"Lichtwarck B, Tvera A-M, Roen I. Targeted Interdisciplinary Model for Evaluation and Treatment of neuropsychiatric symptoms \u2013 Manual, 2e. Ottestad, Norway: Centre for Old Age Psychiatric Research, Innlandet Hospital Trust; 2017."},{"issue":"1","key":"1049_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jagp.2017.05.015","volume":"26","author":"B Lichtwarck","year":"2018","unstructured":"\u2022 Lichtwarck B, Selbaek G, Kirkevold O, Rokstad AMM, Benth JS, Lindstrom JC, et al. Targeted interdisciplinary model for evaluation and treatment of neuropsychiatric symptoms: a cluster randomized controlled trial. Am J Geriatr Psychiatry. 2018;26(1):25\u201338 This is a recent RCT on a manualized approach (TIME) used in the treatment of moderate to severe agitation in people with dementia.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"12","key":"1049_CR14","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1097\/JGP.0b013e31820dcbb6","volume":"19","author":"E Holtta","year":"2011","unstructured":"Holtta E, Laakkonen ML, Laurila JV, Strandberg TE, Tilvis R, Kautiainen H, et al. The overlap of delirium with neuropsychiatric symptoms among patients with dementia. Am J Geriatr Psychiatry. 2011;19(12):1034\u201341.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1049_CR15","unstructured":"Food and Drug Administration. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. 2018. March 16 2019. Available from: \n                      https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm611032.htm\n                      \n                    ."},{"issue":"4","key":"1049_CR16","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/jgs.15248","volume":"66","author":"RLP Jump","year":"2018","unstructured":"Jump RLP, Crnich CJ, Mody L, Bradley SF, Nicolle LE, Yoshikawa TT. Infectious diseases in older adults of long-term care facilities: update on approach to diagnosis and management. J Am Geriatr Soc. 2018;66(4):789\u2013803.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"1049_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/jgs.12070","volume":"61","author":"E D'Agata","year":"2013","unstructured":"D'Agata E, Loeb MB, Mitchell SL. Challenges in assessing nursing home residents with advanced dementia for suspected urinary tract infections. J Am Geriatr Soc. 2013;61(1):62\u20136.","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"1049_CR18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jamda.2018.05.001","volume":"19","author":"LW van Buul","year":"2018","unstructured":"\u2022 van Buul LW, Vreeken HL, Bradley SF, Crnich CJ, Drinka PJ, Geerlings SE, et al. The development of a decision tool for the empiric treatment of suspected urinary tract infection in frail older adults: a Delphi consensus procedure. J Am Med Dir Assoc. 2018;19(9):757\u201364 This is a decision tool based on a consensus consensus regarding treatment of suspected UTI in older adults.","journal-title":"J Am Med Dir Assoc"},{"issue":"6","key":"1049_CR19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jamda.2014.12.016","volume":"16","author":"SA Hendriks","year":"2015","unstructured":"Hendriks SA, Smalbrugge M, Galindo-Garre F, Hertogh CM, van der Steen JT. From admission to death: prevalence and course of pain, agitation, and shortness of breath, and treatment of these symptoms in nursing home residents with dementia. J Am Med Dir Assoc. 2015;16(6):475\u201381.","journal-title":"J Am Med Dir Assoc"},{"issue":"6","key":"1049_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40263-016-0342-7","volume":"30","author":"BS Husebo","year":"2016","unstructured":"\u2022\u2022 Husebo BS, Achterberg W, Flo E. Identifying and managing pain in people with Alzheimer's disease and other types of dementia: a systematic review. CNS Drugs. 2016;30(6):481\u201397 A systematic review on managing pain in people with dementia.","journal-title":"CNS Drugs"},{"key":"1049_CR21","doi-asserted-by":"crossref","unstructured":"\u2022 Bullock L, Bedson J, Jordan JL, Bartlam B, Chew-Graham CA, Campbell P. Pain assessment and pain treatment for community-dwelling people with dementia: a systematic review and narrative synthesis. Int J Geriatr psychiatry. 2019; Very recent review on pain assessment and treatment in community dwelling people with dementia.","DOI":"10.1002\/gps.5078"},{"issue":"3","key":"1049_CR22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jagp.2017.08.005","volume":"26","author":"Y Jaidi","year":"2018","unstructured":"\u2022 Jaidi Y, Nonnonhou V, Kanagaratnam L, Bertholon LA, Badr S, Noel V, et al. Reduction of the anticholinergic burden makes it possible to decrease behavioral and psychological symptoms of dementia. Am J Geriatr Psychiatry. 2018;26(3):280\u20138 This study shows that reducing anticholinergic burden makes it possible to reduce BPSD and caregiver burden.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1049_CR23","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 American Geriatrics Society beers criteria\u00ae update expert panel American Geriatrics Society 2019 Updated AGS Beers Criteria\u00ae for Potentially. Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019. \n                      https:\/\/doi.org\/10.1111\/jgs.15767.\n                      \n                     Recent update of Beers Criteria for potentially inappropriate medication use in older adults.","DOI":"10.1111\/jgs.15767."},{"issue":"2","key":"1049_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/gps.4302","volume":"31","author":"S Rongen","year":"2016","unstructured":"Rongen S, Kramers C, O'Mahony D, Feuth TB, Olde Rikkert MG, Ahmed AI. Potentially inappropriate prescribing in older patients admitted to psychiatric hospital. Int J Geriatr Psychiatry. 2016;31(2):137\u201345.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"39","key":"1049_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18610","volume":"18","author":"G Livingston","year":"2014","unstructured":"Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, et al. A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia. Health Technol Assess. 2014;18(39):1\u2013226.","journal-title":"Health Technol Assess"},{"key":"1049_CR26","unstructured":"\u2022\u2022 Brasure M, Jutkowitz E, Fuchs E, Nelson VA, Kane RA, Shippee T, et al. AHRQ comparative effectiveness reviews. Nonpharmacologic interventions for agitation and aggression in dementia. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016. This review compares the effectiveness of nonpharmacological interventions for agitation and aggression in dementia."},{"issue":"3","key":"1049_CR27","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3233\/JAD-151011","volume":"52","author":"S Vandepitte","year":"2016","unstructured":"Vandepitte S, Van Den Noortgate N, Putman K, Verhaeghe S, Faes K, Annemans L. Effectiveness of supporting informal caregivers of people with dementia: a systematic review of randomized and non-randomized controlled trials. J Alzheimers Dis. 2016;52(3):929\u201365.","journal-title":"J Alzheimers Dis"},{"key":"1049_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12877-016-0280-8","volume":"16","author":"KJ Gilhooly","year":"2016","unstructured":"Gilhooly KJ, Gilhooly ML, Sullivan MP, McIntyre A, Wilson L, Harding E, et al. A meta-review of stress, coping and interventions in dementia and dementia caregiving. BMC Geriatr. 2016;16:106.","journal-title":"BMC Geriatr"},{"issue":"3","key":"1049_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/nur.21869","volume":"41","author":"K Williams","year":"2018","unstructured":"Williams K, Blyler D, Vidoni ED, Shaw C, Wurth J, Seabold D, et al. A randomized trial using telehealth technology to link caregivers with dementia care experts for in-home caregiving support: FamTechCare protocol. Res Nurs Health. 2018;41(3):219\u201327.","journal-title":"Res Nurs Health"},{"key":"1049_CR30","doi-asserted-by":"crossref","unstructured":"Gitlin LN, Marx KA, Alonzi D, Kvedar T, Moody J, Trahan M, et al. Feasibility of the tailored activity program for hospitalized (TAP-H) patients with behavioral symptoms. Gerontologist. 2016:gnw052.","DOI":"10.1093\/geront\/gnw052"},{"issue":"2","key":"1049_CR31","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/jgs.15194","volume":"66","author":"LN Gitlin","year":"2018","unstructured":"Gitlin LN, Arthur P, Piersol C, Hessels V, Wu SS, Dai Y, et al. Targeting behavioral symptoms and functional decline in dementia: a randomized clinical trial. J Am Geriatr Soc. 2018;66(2):339\u201345.","journal-title":"J Am Geriatr Soc"},{"issue":"1 Suppl","key":"1049_CR32","doi-asserted-by":"publisher","first-page":"70s","DOI":"10.1177\/1090198114531782","volume":"41","author":"MA Trahan","year":"2014","unstructured":"Trahan MA, Kuo J, Carlson MC, Gitlin LN. A systematic review of strategies to foster activity engagement in persons with dementia. Health Educ Behav. 2014;41(1 Suppl):70s\u201383s.","journal-title":"Health Educ Behav"},{"issue":"suppl_1","key":"1049_CR33","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1093\/geront\/gnx167","volume":"58","author":"Kezia Scales","year":"2018","unstructured":"\u2022\u2022 Scales K, Zimmerman S, Miller SJ. Evidence-Based Nonpharmacological Practices to Address Behavioral and Psychological Symptoms of DementiaEvidence-Based Nonpharmacological Practices to Address Behavioral and Psychological Symptoms of Dementia. Gerontologist. 2018;58(suppl_1):S88\u2013s102. This article provides evidence-based recommendations for nonpharmacological practices for dementia care that are helpful to persons implementing these practices.","journal-title":"The Gerontologist"},{"key":"1049_CR34","doi-asserted-by":"crossref","unstructured":"\u2022 Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs for people with dementia. Cochrane Database Syst Rev. 2015;(4):Cd006489 This is the most updated review of the effects of exercise programs in persons with dementia.","DOI":"10.1002\/14651858.CD006489.pub4"},{"issue":"Pt B","key":"1049_CR35","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.arr.2015.09.001","volume":"24","author":"S Barreto Pde","year":"2015","unstructured":"Barreto Pde S, Demougeot L, Pillard F, Lapeyre-Mestre M, Rolland Y. Exercise training for managing behavioral and psychological symptoms in people with dementia: a systematic review and meta-analysis. Ageing Res Rev. 2015;24(Pt B):274\u201385.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"1049_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1017\/S1041610218000534","volume":"31","author":"HC Kales","year":"2019","unstructured":"\u2022\u2022 Kales HC, Lyketsos CG, Miller EM, Ballard C. Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus. Int Psychogeriatr. 2019;31(1):83\u201390 This is the most recent published consensus report on management of BPSD.","journal-title":"Int Psychogeriatr"},{"issue":"7\u20138","key":"1049_CR37","doi-asserted-by":"publisher","first-page":"e1360","DOI":"10.1111\/jocn.14007","volume":"27","author":"LE Legere","year":"2018","unstructured":"Legere LE, McNeill S, Schindel Martin L, Acorn M, An D. Nonpharmacological approaches for behavioural and psychological symptoms of dementia in older adults: a systematic review of reviews. J Clin Nurs. 2018;27(7\u20138):e1360\u2013e76.","journal-title":"J Clin Nurs"},{"issue":"4","key":"1049_CR38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1192\/bjp.bp.114.148130","volume":"207","author":"V Orgeta","year":"2015","unstructured":"\u2022 Orgeta V, Qazi A, Spector A, Orrell M. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment: systematic review and meta-analysis. Br J Psychiatry. 2015;207(4):293\u20138 A review of six trials of psychological treatments found evidence of efficacy for depression and anxiety in milder forms of cognitive impairment.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"1049_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40501-013-0003-0","volume":"1","author":"DN Kiosses","year":"2014","unstructured":"Kiosses DN, Alexopoulos GS. Problem-solving therapy in the elderly. Curr Treat Options Psychiatry. 2014;1(1):15\u201326.","journal-title":"Curr Treat Options Psychiatry"},{"key":"1049_CR40","doi-asserted-by":"crossref","unstructured":"Abraha I, Rimland JM, Lozano-Montoya I, Dell'Aquila G, Velez-Diaz-Pallares M, Trotta FM, et al. Simulated presence therapy for dementia. Cochrane Database Syst Rev. 2017;(4):Cd011882.","DOI":"10.1002\/14651858.CD011882.pub2"},{"issue":"1","key":"1049_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jnnp-2014-308112","volume":"86","author":"J Wang","year":"2015","unstructured":"\u2022 Wang J, Yu JT, Wang HF, Meng XF, Wang C, Tan CC, et al. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015;86(1):101\u20139 This is one of a number of recent reviews of medications options for the treatment of BPSD.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"1049_CR42","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/14656566.2017.1307340","volume":"18","author":"AP Porsteinsson","year":"2017","unstructured":"Porsteinsson AP, Antonsdottir IM. An update on the advancements in the treatment of agitation in Alzheimer's disease. Expert Opin Pharmacother. 2017;18(6):611\u201320.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"1049_CR43","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/0269881117744996","volume":"32","author":"SJ Davies","year":"2018","unstructured":"Davies SJ, Burhan AM, Kim D, Gerretsen P, Graff-Guerrero A, Woo VL, et al. Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia. J Psychopharmacol. 2018;32(5):509\u201323.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"1049_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/gps.4566","volume":"32","author":"N Farina","year":"2017","unstructured":"\u2022 Farina N, Morrell L, Banerjee S. What is the therapeutic value of antidepressants in dementia? A narrative review. Int J Geriatr Psychiatry. 2017;32(1):32\u201349 The authors review the literature on the role of antidepressant for addressing BPSD.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"7","key":"1049_CR45","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jama.2014.93","volume":"311","author":"Anton P. Porsteinsson","year":"2014","unstructured":"\u2022\u2022 Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trialEffect of Citalopram on Agitation in Alzheimer Disease. Jama. 2014;311(7):682\u201391. This seminal study demonstrated the efficacy of citalopram for agitation in patients with Alzheimer\u2019s disease, but also confirmed that citalopram can cause QT prolongation.","journal-title":"JAMA"},{"issue":"2","key":"1049_CR46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/0891988715601735","volume":"29","author":"ME Peters","year":"2016","unstructured":"Peters ME, Vaidya V, Drye LT, Devanand DP, Mintzer JE, Pollock BG, et al. Citalopram for the treatment of agitation in Alzheimer dementia: genetic influences. J Geriatr Psychiatry Neurol. 2016;29(2):59\u201364.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"3","key":"1049_CR47","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bcp.12997","volume":"82","author":"T Ho","year":"2016","unstructured":"Ho T, Pollock BG, Mulsant BH, Schantz O, Devanand DP, Mintzer JE, et al. R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. Br J Clin Pharmacol. 2016;82(3):784\u201392. \n                      https:\/\/doi.org\/10.1111\/bcp.12997\n                      \n                    .","journal-title":"Br J Clin Pharmacol"},{"key":"1049_CR48","doi-asserted-by":"crossref","unstructured":"McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev. 2016;(11):Cd009178.","DOI":"10.1002\/14651858.CD009178.pub3"},{"issue":"2","key":"1049_CR49","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/1533317513507375","volume":"29","author":"M Nardell","year":"2014","unstructured":"Nardell M, Tampi RR. Pharmacological treatments for frontotemporal dementias: a systematic review of randomized controlled trials. Am J Alzheimers Dis Other Dement. 2014;29(2):123\u201332.","journal-title":"Am J Alzheimers Dis Other Dement"},{"issue":"2","key":"1049_CR50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/psyg.12191","volume":"17","author":"FM Scoralick","year":"2017","unstructured":"Scoralick FM, Louzada LL, Quintas JL, Naves JO, Camargos EF, Nobrega OT. Mirtazapine does not improve sleep disorders in Alzheimer's disease: results from a double-blind, placebo-controlled pilot study. Psychogeriatrics. 2017;17(2):89\u201396.","journal-title":"Psychogeriatrics."},{"issue":"6","key":"1049_CR51","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.psym.2014.01.010","volume":"55","author":"L De Picker","year":"2014","unstructured":"De Picker L, Van Den Eede F, Dumont G, Moorkens G, Sabbe BG. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. Psychosomatics. 2014;55(6):536\u201347.","journal-title":"Psychosomatics."},{"issue":"3","key":"1049_CR52","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4140\/TCP.n.2016.139","volume":"31","author":"TS Viramontes","year":"2016","unstructured":"Viramontes TS, Truong H, Linnebur SA. Antidepressant-induced Hyponatremia in older adults. Consult Pharm. 2016;31(3):139\u201350.","journal-title":"Consult Pharm"},{"issue":"5","key":"1049_CR53","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/2040622316658463","volume":"7","author":"RR Tampi","year":"2016","unstructured":"Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229\u201345.","journal-title":"Ther Adv Chronic Dis"},{"key":"1049_CR54","unstructured":"\u2022 Maglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, et al. AHRQ comparative effectiveness reviews. Off-label use of atypical antipsychotics: An update. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011. Though a bit dated at this point, this AHRQ review\u2019s conclusions that risperidone, olanzapine and aripiprazole are the antipsychotics most likely to improve agitation, psychosis and overall BPSD are still valid."},{"issue":"5","key":"1049_CR55","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1176\/appi.ajp.2015.173501","volume":"173","author":"VI Reus","year":"2016","unstructured":"\u2022\u2022 Reus VI, Fochtmann LJ, Eyler AE, Hilty DM, Horvitz-Lennon M, Jibson MD, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543\u20136 This APA Practice Guideline is a state-of-the art review of the use of antipsychotics for BPSD.","journal-title":"Am J Psychiatry"},{"issue":"15","key":"1049_CR56","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa061240","volume":"355","author":"LS Schneider","year":"2006","unstructured":"\u2022 Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355(15):1525\u201338 The CATIE-AD study represents the most comprehensive attempt to date to determine the role of antipsychotics in the treatment of BPSD.","journal-title":"N Engl J Med"},{"key":"1049_CR57","doi-asserted-by":"crossref","unstructured":"Van Leeuwen E, Petrovic M, van Driel ML, De Sutter AI, Vander Stichele R, Declercq T, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018;(3):Cd007726.","DOI":"10.1002\/14651858.CD007726.pub3"},{"issue":"7","key":"1049_CR58","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/1533317514524813","volume":"29","author":"RR Tampi","year":"2014","unstructured":"Tampi RR, Tampi DJ. Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials. Am J Alzheimers Dis Other Dement. 2014;29(7):565\u201374.","journal-title":"Am J Alzheimers Dis Other Dement"},{"issue":"11","key":"1049_CR59","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.mayocp.2017.09.007","volume":"92","author":"EK St Louis","year":"2017","unstructured":"St Louis EK, Boeve BF. REM sleep behavior disorder: diagnosis, clinical implications, and future directions. Mayo Clin Proc. 2017 Nov;92(11):1723\u201336. \n                      https:\/\/doi.org\/10.1016\/j.mayocp.2017.09.007\n                      \n                    .","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"1049_CR60","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1176\/appi.ajp.2015.14121582","volume":"172","author":"C Stinton","year":"2015","unstructured":"\u2022 Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, et al. Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. Am J Psychiatry. 2015;172(8):731\u201342 After Alzheimer\u2019s disease, one of the most common causes of dementia is Lewy body disease, which is notable for its significant risk of BPSD. This review covers treatments for LBD.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"1049_CR61","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jamda.2014.11.002","volume":"16","author":"C Ballard","year":"2015","unstructured":"Ballard C, Thomas A, Gerry S, Yu LM, Aarsland D, Merritt C, et al. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD). J Am Med Dir Assoc. 2015;16(4):316\u201322.","journal-title":"J Am Med Dir Assoc"},{"issue":"6","key":"1049_CR62","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1177\/1060028017693029","volume":"51","author":"KM Bozymski","year":"2017","unstructured":"Bozymski KM, Lowe DK, Pasternak KM, Gatesman TL, Crouse EL. Pimavanserin: a novel antipsychotic for Parkinson's disease psychosis. Ann Pharmacother. 2017;51(6):479\u201387.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"1049_CR63","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","volume":"17","author":"C Ballard","year":"2018","unstructured":"Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 2018;17(3):213\u201322.","journal-title":"Lancet Neurol"},{"key":"1049_CR64","doi-asserted-by":"crossref","unstructured":"Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanctot KL. Pharmacological interventions for apathy in Alzheimer's disease. Cochrane Database Syst Rev. 2018;(5):Cd012197.","DOI":"10.1002\/14651858.CD012197.pub2"},{"key":"1049_CR65","doi-asserted-by":"crossref","unstructured":"\u2022 Padala PR, Padala KP, Lensing SY, Ramirez D, Monga V, Bopp MM, et al. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled TrialMethylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer\u2019s Disease: A Double-Blind, Randomized, Placebo-Controlled Trial. Am J Psychiatry. 2018;175(2):159\u201368. The most rigorous study to date of the use of a stimulant for apathy due to dementia demonstrated efficacy but also raised concerns about tolerability, specifically increased blood pressure.","DOI":"10.1176\/appi.ajp.2017.17030316"},{"issue":"12","key":"1049_CR66","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jama.2015.10214","volume":"314","author":"JL Cummings","year":"2015","unstructured":"Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. Jama. 2015;314(12):1242\u201354.","journal-title":"Jama."},{"key":"1049_CR67","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/JGP.0b013e3181ab8c61","volume":"17","author":"LY Wang","year":"2009","unstructured":"Wang LY, Shofer JB, Rohde K, Hart KL, Hoff DJ, McFall YH, et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry. 2009;17:744\u201351.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"1049_CR68","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jagp.2018.01.002","volume":"26","author":"TS Kaster","year":"2018","unstructured":"Kaster TS, Blumberger DM. Palliating severe refractory neuropsychiatric symptoms of dementia: is there a role for electroconvulsive therapy? Am J Geriatr Psychiatry. 2018;26(4):435\u20137.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"1049_CR69","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jagp.2017.09.023","volume":"26","author":"JF van den Berg","year":"2018","unstructured":"van den Berg JF, Kruithof HC, Kok RM, Verwijk E, Spaans HP. Electroconvulsive therapy for agitation and aggression in dementia: a systematic review. Am J Geriatr Psychiatry. 2018;26(4):419\u201334.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1049_CR70","doi-asserted-by":"crossref","unstructured":"Walaszek A, Behavioral and psychological symptoms of dementia, American Psychiatric Association Publishing 2019 (in press).","DOI":"10.1176\/appi.books.9781615372676"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-019-1049-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-019-1049-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-019-1049-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T19:35:01Z","timestamp":1593459301000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-019-1049-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":70,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["1049"],"URL":"https:\/\/doi.org\/10.1007\/s11920-019-1049-5","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736118219.793576045","asserted-by":"object"}]},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,1]]},"assertion":[{"value":"1 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Laurel J. Bessey declares no potential conflicts of interest.Art Walaszek reports speakers fees from Advocate Lutheran General Hospital, United Way (Madison, WI), University of Wisconsin-Parkside, Medical College of Wisconsin, and Wisconsin Association of Medical Directors. Dr. Walaszek reports an advance on royalties from American Psychiatric Association Publishing, is a core co-leader for National Institute of Ageing, and acted as PI and Co-PI on two grants for US Administration for Community Living.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"66"}}